CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis

Journal of Neuroimmunology

Volumn 102, Issue 1, 2000, Pages 98-106

  Sellebjerg, Finn ^a,b   Madsen, Hans O ^a   Jensen, Claus V ^a   Jensen, Jakob ^a   Garred, Peter ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Sector Diagn Serv Statens S ^*  (Denmark)

Author keywords

CD4 T cells; Cerebrospinal fluid; Chemokine; Matrix metalloproteinase; Multiple sclerosis

Indexed keywords

GELATINASE B; MATRIX METALLOPROTEINASE; CHEMOKINE RECEPTOR CCR5;

ADULT; ALLELE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID; GENETICS; METABOLISM; MYELITIS; PATHOLOGY; PATHOPHYSIOLOGY; REFERENCE VALUE; RISK FACTOR;

ADULT; ALLELES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MULTIPLE SCLEROSIS; MYELITIS; RECEPTORS, CCR5; RECURRENCE; REFERENCE VALUES; RISK FACTORS;

EID: 0033622321     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00166-6     Document Type: Article

References (78)

1. Akhatib G., Cambaiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., Berger E.A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1996;1955-1958.
2. Andersson M., Alvarez Cermeno J., Bernardi G., Cogato I., Fredman P., Frederiksen J., Fredrikson S., Gallo P., Grimaldi L.M., Gronning M.et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. Neurosurg. Psychiatry. 57:1994;897-902.
3. Annunziato F., Galli G., Cosmi L., Romagnani P., Manetti R., Maggi E., Romagnani S. Molecules associated with human Th1 and Th2 cells. Eur. Cytokine Network. 9:1998;12-16. suppl.
4. Anthony D.C., Ferguson B., Matyszak M.K., Miller K.M., Esiri M.M., Perry M.M. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 23:1997;406-415.
5. Baggiolini M. Chemokines and leukocyte traffic. Nature. 392:1998;565-568.
6. Balashov K.E., Rottman J.B., Weiner H.L., Hancock W.W. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1alfa and IP-10 are increased in demyelinating brain lesions. Proc. Natl. Acad. Sci. U.S.A. 96:1999;6873-6878.
7. Bennetts B.H., Teutsch S.M., Buhler M.M., Heard R.N., Stewart G.J. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum. Immunol. 58:1997;52-59.
8. Blennow K., Fredman P., Wallin A., Gottfries C.-G., Karlsson I., Långstr¢m G., Skoog I., Svennerholm L., Wikkelsö C. Protein analysis in cerebrospinal fluid: II. Reference values derived from healthy individuals 18-88 years of age. Eur. Neurol. 33:1993;129-133.
9. Bleul C.C., Wu L., Hoxie J.A., Springer T.A., Mackay C.R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 94:1997;1925-1930.
10. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsatti A., Sozzani S., Allavena P., Gray P.A., Mantovani A., Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187:1998;129-134.
11. Brosnan C.F., Bornstein M.B., Bloom B.R. The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyelitis. J. Immunol. 126:1981;614-620.
12. Butterfield R.J., Blankenhorn E.P., Roper R.J., Zachary J.F., Doerge R.W., Sudweeks J., Rose J., Teuscher C. Genetic analysis of disease subtypes and sexual dimorphisms in mouse experimental allergic encephalomyelitis (EAE): relapsing/remitting and monophasic remitting/nonrelapsing EAE are immunogenetically distinct. J. Immunol. 162:1999;3096-3102.
13. Compston, A., 1998. Genetic susceptibility to multiple sclerosis. In: Compston, A., Ebers, G., Lassmann, H., McDonald, I., Matthews, B., Wekerle, H. (Eds.), McAlpine's Multiple Sclerosis. Churchill Livingstone, London, pp. 101-142.
14. Coraddu F., Sawcer S., Feakes R., Chataway J., Broadley S., Jones H.B., Clayton D., Gray J., Smith S., Taylor C., Goodfellow P.N., Compston A. HLA typing in the United Kingdom multiple sclerosis genome screen. Neurogenetics. 2:1998;24-33.
15. Cossins J.A., Clements J.M., Ford J., Miller K.M., Pigott R., Vos W., van der Valk P., de Groot C.J.A. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. (Berl.). 94:1997;590-598.
16. Cuzner M.L., Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol. 94:1999;1-14.
17. Cuzner M.L., Gveric D., Strand C., Loughlin A.J., Paemen L., Opdenakker G., Newcombe J. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55:1996;1194-1204.
18. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Likmets R., Goedert J.J., Buchbinder S.P., Vittinghoff E., Gomperts E., Donfield S., Vlahov D., Kaslow R., Saah A., Rinaldo C., Detels R., O'Brien S.J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science. 273:1996;1856-1862.
19. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:1996;661-666.
20. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., Cayanan C., Maddon P.J., Koup R.A., Moore J.P., Paxton W.A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:1996;667-673.
21. Ebers G.C., Kukay K., Bulmjan D.E., Sadovnick A.D., Rice G., Anderson C., Armstrong H., Cousin K., Bell R.B. A full genome search in multiple sclerosis. Nat. Genet. 13:1996;472-476.
22. Eugen-Olsen J., Iversen A.K., Garred P., Koppelhus U., Pedersen C., Benfield T.L., Sorensen A.M., Katzenstein T., Dickmeiss E., Gerstoft J., Skinh¢j P., Svejgaard A., Nielsen J.O., Hofmann B. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS. 11:1997;305-310.
23. Fiten P., Vandenbroeck K., Dubois B., Coillie E.V., Nelissen I., Damme J.V., Ligers A., Hillert J., Andersson M., Olsson T., Opdenakker G. Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of teh association between monocyte chmotactic protein-3 alleles and multiple sclerosis development. J. Neuroimmunol. 95:1999;195-201.
24. Frederiksen J.L., Larsson H.B.W., Christiansen P., Sellebjerg F.T., Olesen J. Blood-brain barrier impairment in acute optic neuritis evaluated by Gadolinium-DTPA enhanced MRI and CSF studies. Eur. J. Neurol. 3:1996;560-566.
25. Fredrikson S., Karlsson Parra A., Olsson T., Link H. HLA-DR antigen expression on T cells from cerebrospinal fluid in multiple sclerosis and aseptic meningo-encephalitis. Clin. Exp. Immunol. 68:1987;298-304.
26. Fredrikson S., Link H., Eneroth P. CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurol. Scand. 75:1987;352-355.
27. Garred P., Madsen H.O., Petersen J., Marquart H., Hansen T.M., Sørensen S.S., Volck B., Svejgaard A., Andersen V. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J. Rheumatol. 25:1998;1462-1465.
28. Gay F.W., Drye T.J., Dick G.W.A., Esiri M.M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain. 120:1997;1461-1483.
29. Gijbels K., Masure S., Carton H., Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory disorders. J. Neuroimmunol. 41:1992;29-34.
30. Hafler D.A., Fox D.A., Manning M.E., Schlossman S.F., Reinherz E.L., Weiner H.L. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N. Engl. J. Med. 312:1985;1405-1411.
31. Huitinga I., van Rooijen N., de Groot C.J., Uitdehaag B.M., Dijkstra C.D. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172:1990;1025-1033.
32. Huitinga I., Ruuls S.R., Jung S., Van Rooijen N., Hartung H.P., Dijkstra C.D. Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin. Exp. Immunol. 100:1995;344-351.
33. Karpus W.J., Kennedy K.J. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J. Leuk. Biol. 62:1997;681-687.
34. Karpus W.J., Ransohoff R.M. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J. Immunol. 161:1998;2667-2671.
35. Karpus W.J., Lukacs N.W., McRae B.L., Strieter R.M., Kunkel S.L., Miller S.D. An important role for the chemokine macrophage inflammatory protein-1alfa in the pathogenesis of the T cell mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol. 155:1995;5003-5010.
36. Kuokkanen S., Gscwend M., Rioux J.D., Daly M.J., Terwilliger J.D., Tienari P.J., Wikström J., Palo J., Stein L.D., Hudson T.J., Lander E.S., Peltonen L. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am. J. Hum. Genet. 61:1998;1379-1387.
37. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
38. Leppert D., Waubant E., Bürk M.R., Oksenberg J.R., Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1996;846-852.
39. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., Miller K.M., Hauser S.L., Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain. 121:1998;2327-2334.
40. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell. 86:1996;367-377.
41. Loetscher P., Uguccioni M., Bordoli L., Baggiolini M., Moser B. CCR5 is characteristic of Th1 lymphocytes. Nature. 391:1998;344-345.
42. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
43. Luster A.D. Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:1998;436-445.
44. The Multicenter AIDS Cohort Study (MACS), McDermott D.H., Zimmerman P.A., Guignard F., Kleeberger C.A., Leitman S.F., Murphy P.M. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet. 352:1998;866-870.
45. Miyagishi R., Kikuchi S., Fukazawa T., Tashiro K. Macrophage inflammatory protein-1alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J. Neurol. Sci. 129:1995;223-227.
46. Naruse K., Ueno M., Satoh T., Nomiyama H., Tei H., Takeda M., Ledbetter D.H., Coillie E.V., Opdenakker G., Gunge N., Sakaki Y., Iio M., Miura R. A YAC contig of the human CC chemokine genes clustered on chromosome 17q11.2. Genomics. 34:1996;236-240.
47. Olerup O., Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 h: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 39:1992;225-235.
48. Ott M., Demisch L., Engelhardt W., Fischer P.-A. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis. J. Neurol. 241:1993;108-114.
49. Paemen L., Olsson T., Söderström M., Van Damme J., Opdenakker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur. J. Neurol. 1:1994;55-63.
50. Paty D.W., Oger J.J., Kastrukoff L.F., Hashimoto S.A., Hooge J.P., Eisen A.A., Eisen K.A., Purves S.J., Low M.D., Brandejs V.et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 38:1988;180-185.
51. Poser C.M. Onset symptoms of multiple sclerosis [letter]. J. Neurol. Neurosurg. Psychiatry. 58:1995;254-255.
52. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
53. Qin S., Rottman J.B., Myers P., Kassam N., Weinblatt M., Loetscher M., Koch A.E., Moser B., Mackay C.R. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101:1998;746-754.
54. Reinhold D., Hemmer B., Gran B., Born I., Faust J., Neubert K., McFarland H.F., Martin R., Ansorge S. Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones. J. Neuroimmunol. 87:1998;203-209.
55. Rottman J.B., Ganley K.P., Williams K., Wu L., Mackay C.R., Ringler D.J. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am. J. Pathol. 151:1997;1341-1351.
56. Rudick R.A., Cookfair D.L., Simonian N.A., Ransohoff R.M., Richert J.R., Jacobs L.D., Herndon R.M., Salazar A.M., Fischer J.S., Granger C.V., Goodkin D.E., Simon J.H., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNb-1a) for relapsing multiple sclerosis. J. Neuroimmunol. 93:1999;8-14.
57. Sallusto F., Lenig D., Mackay C.R., Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187:1998;875-883.
58. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382:1996;722-725.
59. Sawcer S., Jones H.B., Feakes R., Gray J., Smaldon N., Chataway J., Robertson N., Clayton D., Goodfellow P.N., Compston A. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 [see comments]. Nat. Genet. 13:1996;464-468.
60. Sørensen T.L., Ransohoff R.M. Etiology and pathogenesis of multiple sclerosis. Semin. Neurol. 18:1998;287-294.
61. Sørensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., Qin S., Rottman J., Sellebjerg F., Strieter R.M., Frederiksen J.L., Ransohoff R.M. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103:1999;807-815.
62. Sellebjerg F., Christiansen M. Qualitative assessment of intrathecal IgG synthesis by isoelectric focusing and immunodetection: interlaboratory reproducibility and interobserver agreement. Scand. J. Clin. Lab. Invest. 56:1996;135-143.
63. Sellebjerg F., Christiansen M., Nielsen P.M., Frederiksen J.L. Cerebrospinal fluid measures of disease activity in multiple sclerosis. Multiple Sclerosis. 4:1998;475-479.
64. Sellebjerg F., Frederiksen J.L., Nielsen P.M., Olesen J. A double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology. 51:1998;529-534.
65. Sellebjerg F., Jensen J., Ryder L.P. Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis. J. Neuroimmunol. 84:1998;179-187.
66. Sellebjerg F., Schaldemose Nielsen H., Frederiksen J.L., Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 52:1999;1479-1484.
67. Simpson J.E., Newcombe J., Cuzner M.L., Woodroofe M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 84:1998;238-249.
68. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1993;301-314.
69. Sriram S., Rodriguez M. Indictment of the microglia as the villain in multiple sclerosis. Neurology. 48:1997;464-470.
70. Stüve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., Yong V.W. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40:1996;853-863.
71. Svenningsson A., Hansson G.K., Andersen O., Andersson R., Patarroyo M., Stemme S. Adhesion molecule expression on cerebrospinal fluid T lymphocytes: evidence for common recruitment mechanisms in multiple sclerosis, aseptic meningitis, and normal controls. Ann. Neurol. 34:1993;155-161.
72. The Multiple Sclerosis Study Group, a. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group [see comments]. Nat. Genet. 13:1996;469-471.
73. van Engelen B.G.M., Lamers K.J.B., Gabreels F.J.M., Wevers R.A., van Geel W.J.A., Borm G.F. Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin. Chem. 38:1992;813-816.
74. Vingsbo-Lundberg C., Nordquist N., Olofsson P., Sundvall M., Saxne T., Pettersson U., Holmdahl R. Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats. Nat. Genet. 20:1998;401-404.
75. Walker R.W.H., Thompson E.J., McDonald W.I. Cerebrospinal fluid in multiple sclerosis: relationships between immunoglobulins, leucocytes and clinical features. J. Neurol. 232:1985;250-259.
76. Wu L., Paxton W.A., Kassam N., Ruffing N., Rottman J.B., Sullvan N., Choe H., Sodroski J., Newman W., Koup R.A., Mackay C.R. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185:1997;1681-1691.
77. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., Edwards D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21:1998;75-80.
78. Zhou Y., Kurihara T., Ryseck R.P., Yang Y., Ryan C., Loy J., Warr G., Bravo R. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J. Immunol. 160:1998;4018-4025.